WASHINGTON — Military veterans injured between 2001 and 2005 are now retroactively eligible for traumatic injury benefits, even if they never deployed overseas to battle zones in Iraq and Afghanistan.

WASHINGTON — When servicemembers commit suicide, a common misperception is that the extreme act is a response to traumatic battlefield experiences.

WASHINGTON — Mass-casualty management planning that occurred at the Pentagon in the months and days before 9/11 helped medical personnel respond appropriately and saved American lives, according to  retired Lt. Gen. Paul K. Carlton Jr., MD, who was involved in that planning as the Air Force surgeon general.

WASHINGTON — The United States should have a system in place to compensate medical research subjects for injuries incurred during the trials they were a part of, according to a federal report. Currently, the U.S. requires subjects to seek compensation through the federal court system.

WASHINGTON — Since taking office, FDA Commissioner Margaret Hamburg, MD, has pushed for science to play a stronger role in the agency, both in the rationale for its decision-making and in meeting its basic purpose.

WASHINGTON — The U.S. military has implemented programs and strategies to promote psychological resilience among troops as stress from the current conflicts in Iraq and Afghanistan has taken a toll.

Fort Belvoir, VA - The new 120-bed Fort Belvoir Community Hospital (FBCH) is far from the typical hospital with institutional green cinderblock walls lining dark hallways.

BETHESDA, MD — A wave of genetic research projects sparked by last decade’s completion of the Human Genome Project are slowly making their way to fruition. Researchers, many of whom are based at NIH, are busy teasing apart the genetic mechanisms that contribute to disease, as well as finding ways to give physicians the ability to use genomic data to directly treat patients.

WASHINGTON — A new chapter in military medicine is set to begin this month with the opening of the new Walter Reed National Military Medical Center in Bethesda, MD.

WASHINGTON — An antipsychotic medication commonly used by VA to treat combat-related PTSD has been found to have no discernible benefit. Patients taking the drug risperidone (Risperdal) did no better than those taking a placebo, according to a recent VA-run study.